MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials [0.03%]
基于MRI的肌层浸润性膀胱癌新辅助免疫治疗疗效评估：3项前瞻性临床研究中放射科医生间差异及诊断准确性的分析
Joyce Greidanus,Margriet C van Dijk-de Haan,Antonella Messina et al.
Joyce Greidanus et al.
Objective: For patients with muscle-invasive bladder cancer (MIBC), accurate assessment of neoadjuvant therapy response may allow for bladder-sparing strategies, emphasizing the need for accurate, noninvasive response ass...
Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort [0.03%]
内镜下肾保留手术治疗上尿路尿路上皮癌的长期肿瘤结局和功能结局：一项单中心大样本量队列研究
Pietro Scilipoti,Federico Zorzi,Letizia Maria Ippolita Jannello et al.
Pietro Scilipoti et al.
Background: Long-term benchmark data on endoscopic kidney-sparing surgery (eKSS) for upper tract urothelial carcinoma (UTUC) remain limited. Objective: ...
PROTEUS Trial the Day After: Practice Changing or Premature Escalation? [0.03%]
PROTEUS试验的第二天：改变实践还是过早行动？
Isabel Heidegger,Chiara Mercinelli,Giulia Marvaso et al.
Isabel Heidegger et al.
Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer [0.03%]
STAMPEDE大样本转移性雄激素敏感型前列腺癌中二甲双胍的总生存期获益预示着代谢靶向治疗前列腺癌的机会
Cameron E Alexander,Ashwin Sachdeva,Noel W Clarke
Cameron E Alexander
Moein Moradpour,Chae Moon Hong,Sobia Khan et al.
Moein Moradpour et al.
We evaluated quantitative changes in total metastatic tumor burden in patients with metastatic castration-resistant prostate cancer undergoing prostate-specific membrane antigen radioligand therapy (PSMA RLT) using single photon emission co...
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab [0.03%]
恩沃单抗±帕博利珠单抗治疗晚期尿路上皮癌患者时个性化循环肿瘤DNA检测的预后意义
Kevin R Reyes,Ryan Zhu,Cameron Herberts et al.
Kevin R Reyes et al.
Background and objective: Enfortumab vedotin (EV) plus pembrolizumab (P) is the preferred first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC); however, responses remain heterogeneous, and b...
PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients? [0.03%]
PROTEUS：一项改变实践的试验，但我们准备好为所有高危患者接受围手术期阿帕鲁胺了吗？
Giuseppe Di Lorenzo,Francesco Montorsi
Giuseppe Di Lorenzo
Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry [0.03%]
高风险肾细胞癌肾切除术后派姆单抗的现实世界数据——一项国家早期使用计划注册研究
Idir Ouzaid,Pierre Bigot,Morgan Rouprêt
Idir Ouzaid
Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe trial. Eur Urol Oncol 2026;9:404-12 [0.03%]
答乐长来信：Contieri R，Paciotti M，Uleri A等。HuNIRe试验结果：选择性T1期非肌层浸润性膀胱癌患者可以安全地省略第二次经尿道膀胱肿瘤电切术。Eur Urol Oncol 2026;9:404-12
Roberto Contieri,Rodolfo Hurle
Roberto Contieri
Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-12: Pathological Restaging and Omission of Second TURBT in T1 NMIBC [0.03%]
T1期非肌层浸润性膀胱癌患者的二次电切可以被替代：HuNIRe试验的前瞻性结果
Yue Chang
Yue Chang